Forward-looking statements
This site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, without limitation, statements regarding the Company's clinical development plans and timelines, IND-enabling work, regulatory expectations, partnership intentions, and business strategy. Actual results may differ materially from those expressed or implied by such statements due to risks and uncertainties, including those relating to early-stage drug development, preclinical and clinical study outcomes, regulatory review, intellectual property, financing, and competitive conditions. The Company undertakes no obligation to update or revise any forward-looking statement except as required by applicable law.